These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 11797190)

  • 1. Lactacidemia in asymptomatic HIV-infected subjects receiving nucleoside reverse-transcriptase inhibitors.
    Boffito M; Marietti G; Audagnotto S; Raiter R; Di Perri G
    Clin Infect Dis; 2002 Feb; 34(4):558-9. PubMed ID: 11797190
    [No Abstract]   [Full Text] [Related]  

  • 2. Symptomatic hyperlactatemia associated with nucleoside analogue reverse-transcriptase inhibitor use in HIV-infected patients: a report of 24 cases in a resource-limited setting (Uganda).
    Songa PM; Castelnuovo B; Mugasha EB; Ocama P; Kambugu A
    Clin Infect Dis; 2007 Aug; 45(4):514-7. PubMed ID: 17638205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hyperlactataemia and lactic acidosis in HIV-infected patients receiving antiretroviral therapy.
    Calza L; Manfredi R; Chiodo F
    Clin Nutr; 2005 Feb; 24(1):5-15. PubMed ID: 15681097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lactic acidemia in infection with human immunodeficiency virus.
    Carr A
    Clin Infect Dis; 2003 Apr; 36(Suppl 2):S96-S100. PubMed ID: 12652378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nucleoside analogue-induced fatal lactic acidosis in two HIV-infected patients in Singapore.
    Hwang SW; Leo YS
    Singapore Med J; 2001 Jun; 42(6):247-51. PubMed ID: 11547960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk factors for lactic acidosis in HIV-infected patients treated with nucleoside reverse-transcriptase inhibitors: a case-control study.
    Bonnet F; Bonarek M; Morlat P; Mercié P; Dupon M; Gemain MC; Malvy D; Bernard N; Pellegrin JL; Beylot J
    Clin Infect Dis; 2003 May; 36(10):1324-8. PubMed ID: 12746780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Symptomatic hyperlactataemia and lactic acidosis in the era of highly active antiretroviral therapy.
    Eshun-Wilson I; Soentjens P; Zeier M; Taljaard J
    S Afr Med J; 2005 Dec; 95(12):929-30. PubMed ID: 16465351
    [No Abstract]   [Full Text] [Related]  

  • 8. Evidence for mitochondrial toxicity: lactic acidosis as proof of concept.
    Brinkman K
    J HIV Ther; 2001 Mar; 6(1):13-6. PubMed ID: 11501196
    [No Abstract]   [Full Text] [Related]  

  • 9. Non-nucleoside-reverse-transcriptase-inhibitor-based HAART and osteoporosis in HIV-infected subjects.
    Bongiovanni M; Fausto A; Cicconi P; Aliprandi A; Cornalba G; Bini T; Sardanelli F; D'Arminio Monforte A
    J Antimicrob Chemother; 2006 Aug; 58(2):485-6. PubMed ID: 16751202
    [No Abstract]   [Full Text] [Related]  

  • 10. Hyperlactataemia in HIV-infected patients: the role of NRTI-treatment.
    Vrouenraets SM; Treskes M; Regez RM; Troost N; Smulders YM; Weigel HM; Frissen PH; Brinkman K
    Antivir Ther; 2002 Dec; 7(4):239-44. PubMed ID: 12553477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detecting life-threatening lactic acidosis related to nucleoside-analog treatment of human immunodeficiency virus-infected patients, and treatment with L-carnitine.
    Claessens YE; Cariou A; Monchi M; Soufir L; Azoulay E; Rouges P; Goldgran-Toledano D; Branche F; Dhainaut JF
    Crit Care Med; 2003 Apr; 31(4):1042-7. PubMed ID: 12682470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Miller Fisher variant of Guillain-Barré syndrome associated with lactic acidosis and stavudine therapy.
    Shah SS; Rodriguez T; McGowan JP
    Clin Infect Dis; 2003 May; 36(10):e131-3. PubMed ID: 12746793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Symptomatic hyperlactatemia in a patient on nucleoside reverse transcriptase inhibitors.
    Ball SC
    AIDS Read; 2001 Dec; 11(12):593-5. PubMed ID: 11806170
    [No Abstract]   [Full Text] [Related]  

  • 14. Human immunodeficiency virus infection with human granulocytic ehrlichiosis complicated by symptomatic lactic acidosis.
    Springer SA; Altice FL
    Clin Infect Dis; 2003 Jun; 36(12):e162-4. PubMed ID: 12802782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lactic acidosis in an HIV-infected patient receiving highly active antiretroviral therapy.
    Patel V; Hedayati SS
    Nat Clin Pract Nephrol; 2006 Feb; 2(2):109-14; quiz 115. PubMed ID: 16932402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperlactatemia and lactic acidosis: should routine screening be considered?
    Moyle G
    AIDS Read; 2002 Aug; 12(8):344-8. PubMed ID: 12229891
    [No Abstract]   [Full Text] [Related]  

  • 17. Highly active antiretroviral therapy (HAART)-associated lactic acidosis: in vitro effects of combination of nucleoside analogues and protease inhibitors on mitochondrial function and lactic acid production.
    Nerurkar PV; Pearson L; Frank JE; Yanagihara R; Nerurkar VR
    Cell Mol Biol (Noisy-le-grand); 2003 Dec; 49(8):1205-11. PubMed ID: 14983988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fanconi syndrome and lactic acidosis associated with stavudine and lamivudine therapy.
    Nelson M; Azwa A; Sokwala A; Harania RS; Stebbing J
    AIDS; 2008 Jul; 22(11):1374-6. PubMed ID: 18580619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical manifestations of mitochondrial toxicity.
    Walker UA
    J HIV Ther; 2001 Mar; 6(1):17-21. PubMed ID: 11501197
    [No Abstract]   [Full Text] [Related]  

  • 20. Long-term complications of nucleoside reverse transcriptase inhibitor therapy.
    Dieterich DT
    AIDS Read; 2003 Apr; 13(4):176-84, 187. PubMed ID: 12741368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.